EP Patent

EP3495358B8 — Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses

Assigned to Bristol Myers Squibb Co · Expires 2022-06-08 · 4y expired

What this patent protects

Patent listed against Sotyktu.

Drugs covered by this patent

Patent Metadata

Patent number
EP3495358B8
Jurisdiction
EP
Classification
—
Expires
2022-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.